Dantrolene

Overview

Dantrolene (Dantrium®) is a direct-acting skeletal muscle relaxant used in dogs and cats for the management of muscle spasm–related conditions and malignant hyperthermia. Unlike centrally acting agents, it works directly at the level of skeletal muscle.

It is commonly used for conditions such as functional urethral obstruction and muscle spasms, and may also be used in the prevention or treatment of malignant hyperthermia. The drug can be administered orally or intravenously depending on the clinical situation.

Mechanism of Action (MOA): Dantrolene acts directly on skeletal muscle by inhibiting the release of calcium from the sarcoplasmic reticulum. This reduces intracellular calcium availability, leading to decreased muscle contraction and muscle relaxation.

Indications

Dantrolene is used in dogs and cats as a direct-acting muscle relaxant for conditions involving skeletal muscle spasm or abnormal muscle contraction. It may be used in both acute and chronic settings depending on the underlying condition.

• Functional urethral obstruction: Used to reduce urethral muscle tone and relieve obstruction, particularly as part of a multimodal management approach.
• Muscle spasms: Indicated for the management of skeletal muscle spasm associated with conditions such as tetanus or other neuromuscular disorders.
• Malignant hyperthermia: Used for both prevention (oral) and treatment (IV) of malignant hyperthermia episodes.
• Rhabdomyolysis (supportive use): May be used to reduce muscle rigidity and associated complications in selected cases.

Dosage (Reference)

Dog

In dogs, dantrolene can be administered intravenously for acute emergencies or orally for ongoing management of muscle-related conditions. Dose selection depends on the clinical indication.

Cat

In cats, dantrolene is used similarly to dogs, with dosing adjusted based on indication and patient response. Both IV and oral routes may be used depending on clinical needs.

Warnings & Precautions

Dantrolene use requires careful patient selection and monitoring due to the risk of hepatotoxicity and its systemic effects, particularly with repeated or high-dose administration.

• Hepatic disease: Use with extreme caution in patients with preexisting liver dysfunction; risk of hepatotoxicity may increase, especially with chronic use or higher doses.
• Cardiac dysfunction: Use cautiously in patients with severe cardiac disease, as overall tolerance to drug effects may be reduced.
• Pulmonary disease: Use with caution in animals with respiratory compromise; clinical status should be monitored closely.
• Extravasation risk (IV): Injectable formulation has a high pH and may cause local irritation; ensure proper IV catheter placement and monitor the injection site.
• Pregnancy: Crosses the placenta and has demonstrated embryotoxic and teratogenic effects in animal studies; avoid use unless benefits clearly outweigh risks.
• Nursing animals: Distributed into milk; safety in nursing animals is not established, so use with caution.
• Dose monitoring: No specific antidote for toxicity; careful dose calculation and monitoring are essential to minimize risk.
• Chronic use: Long-term therapy increases the risk of adverse effects, particularly liver toxicity; periodic monitoring is recommended.

Drug Interactions

Clinically relevant interactions with dantrolene are primarily related to additive sedation, effects on neuromuscular function, and increased risk of metabolic or hepatic complications. Careful monitoring is recommended when used with the following drugs.

• Benzodiazepines (e.g., diazepam, midazolam): Increased sedation may occur when used concurrently.
• Other CNS depressants (e.g., acepromazine, dexmedetomidine, phenobarbital, methocarbamol): Additive CNS depression and sedation may be seen.
• Opioids (e.g., morphine, fentanyl): Concurrent use may enhance sedative effects.
• Calcium channel blockers (e.g., amlodipine, diltiazem, verapamil): Risk of severe hyperkalemia and cardiovascular collapse has been reported (particularly in malignant hyperthermia settings); combination is generally not recommended.
• Estrogens (e.g., diethylstilbestrol, estriol): May increase the risk of hepatotoxicity; clinical relevance in veterinary patients is uncertain but caution is advised.
• Neuromuscular blocking agents (e.g., vecuronium): Dantrolene may potentiate neuromuscular blockade, leading to increased muscle weakness.

Side Effects & Overdose

Side Effects

Adverse effects of dantrolene in dogs and cats are generally related to its muscle-relaxant properties and hepatic metabolism. Most effects are dose-dependent and more likely with prolonged or high-dose use.

• Hepatotoxicity: The most significant adverse effect; may occur with chronic use or high doses and requires monitoring of liver function.
• CNS effects: Weakness, sedation, drowsiness, and dizziness may occur due to muscle relaxation and central effects.
• Gastrointestinal effects: May include vomiting, diarrhea, nausea, and decreased appetite.
• Increased urinary frequency: May be observed in some patients during treatment.
• Hyperkalemia (IV use): Reported in dogs; monitor serum potassium when using injectable forms.
• Hypotension: May occur in some patients, particularly with systemic effects.

Overdose

There is no specific antidote for dantrolene overdose. Clinical signs are typically related to exaggerated pharmacologic effects, and treatment is supportive.

• Severe muscle weakness: Marked reduction in muscle tone and mobility.
• Profound sedation: Excessive CNS depression may occur.
• Gastrointestinal signs: Vomiting and diarrhea may be more pronounced.
• Management: Supportive care is the mainstay, including decontamination if recent oral exposure, fluid therapy, and monitoring of vital parameters.
• No antidote: Treatment focuses on symptom management and monitoring.

Key Notes

Practical clinical insights to guide the effective use of dantrolene in dogs and cats:

• Direct muscle action: Unlike many muscle relaxants, dantrolene acts peripherally at the skeletal muscle level rather than centrally.
• Route selection: IV administration is reserved for acute, life-threatening situations, while oral therapy is preferred for ongoing management.
• Variable absorption: Oral bioavailability and pharmacokinetics can vary significantly between patients, requiring individualized dosing.
• Rapid absorption in dogs: Oral dosing in dogs results in relatively quick absorption and short half-life, influencing dosing frequency.
• Protein binding: The drug is substantially bound to plasma proteins, which may influence distribution and drug interactions.
• Metabolism: Primarily metabolized in the liver, with metabolites excreted in urine.
• Clinical monitoring focus: In addition to routine monitoring, attention should be given to body temperature (in hyperthermia cases) and urinary patterns during therapy.